Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > PRQR ProQR Therapeutics > Detailed Quotes

PRQR ProQR Therapeutics

0.760
+0.004+0.53%
Trading Session 09/30 12:02 ET
High
0.793
Open
0.761
Turnover
126.72K
Low
0.740
Pre Close
0.756
Volume
164.65K
Market Cap
54.24M
P/E(TTM)
Loss
52wk High
8.670
Shares
71.36M
P/E(Static)
Loss
52wk Low
0.530
Float Cap
50.56M
Bid/Ask %
42.86%
Historical High
27.600
Shs Float
66.52M
Volume Ratio
1.09
Historical Low
0.530
Dividend TTM
--
Div Yield TTM
--
P/B
0.60
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.25%
Amplitude
7.04%
Avg Price
0.769
Lot Size
1
Float Cap
50.56M
Bid/Ask %
42.86%
Historical High
27.600
Shs Float
66.52M
Volume Ratio
1.09
Historical Low
0.530
Dividend TTM
--
P/B
0.60
Dividend LFY
--
Turnover Ratio
0.25%
Amplitude
7.04%
Avg Price
0.769
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
CEO: Mr. Daniel de Boer
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...